Cargando…
Mechanisms of disease: pulmonary arterial hypertension
Our understanding of, and approach to, pulmonary arterial hypertension has undergone a paradigm shift in the past decade. Once a condition thought to be dominated by increased vasoconstrictor tone and thrombosis, pulmonary arterial hypertension is now seen as a vasculopathy in which structural chang...
Autores principales: | Schermuly, Ralph T., Ghofrani, Hossein A., Wilkins, Martin R., Grimminger, Friedrich |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7097518/ https://www.ncbi.nlm.nih.gov/pubmed/21691314 http://dx.doi.org/10.1038/nrcardio.2011.87 |
Ejemplares similares
-
Reply to Bogaard et al.: Emphysema Is—at the Most—Only a Mild Phenotype in the Sugen/Hypoxia Rat Model of Pulmonary Arterial Hypertension
por: Kojonazarov, Baktybek, et al.
Publicado: (2019) -
Effects of riociguat in severe experimental pulmonary hypertension
por: Kojonazarov, Baktybek, et al.
Publicado: (2011) -
Glycogen Synthase Kinase 3beta Contributes to Proliferation of Arterial Smooth Muscle Cells in Pulmonary Hypertension
por: Sklepkiewicz, Piotr, et al.
Publicado: (2011) -
Therapeutic Potential of Regorafenib—A Multikinase Inhibitor in Pulmonary Hypertension
por: Veeroju, Swathi, et al.
Publicado: (2021) -
The soluble guanylate cyclase stimulator riociguat ameliorates pulmonary hypertension induced by hypoxia and SU5416 in rats
por: Lang, Michaela, et al.
Publicado: (2011)